Palisade Bio

Palisade Bio is a biopharmaceutical company dedicated to developing next-generation precision therapies for immune, inflammatory and fibrotic diseases. Their mission is to create differentiated product candidates for these conditions in markets with significant unmet medical needs. They believe that precision medicine, specifically the targeted delivery of PDE4 inhibitors, can address the efficacy, safety and patient selection concerns associated with current treatments.

Palisade Bio's lead program, PALI-2108, is a microbiota-activated PDE4 inhibitor prodrug in development for moderate-to-severe ulcerative colitis. They have also developed PALI-1908, a similar prodrug for fibrostenotic Crohn’s Disease. Their platform technology utilizes advanced machine learning to identify patients with elevated PDE4 activity, enabling them to pinpoint key markers of disease and predict patient responses to their therapies.

Palisade Bio is a biopharmaceutical company dedicated to developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases. Their mission is to develop differentiated product candidates that target these diseases in established commercial markets where there is a significant unmet medical need. They focus on advancing early-stage product candidates that address efficacy, safety, and patient selection concerns associated with currently available drugs.

Palisade Bio promotes a culture that is transparent, collaborative, solution-oriented, and patient-centric. They value open communication and teamwork, encouraging their employees to work together to overcome challenges and achieve shared goals. The company prioritizes a patient-focused approach, emphasizing the importance of developing treatments that improve the lives of those living with autoimmune, inflammatory, and fibrotic diseases.

Palisade Bio's approach to diversity, equity, and inclusion is not explicitly stated on their website.